Evidence map›Paper›PMID 27690505›Full record

Trial reportExperimental and clinical psychopharmacology2016

Daily relations among affect, urge, targeted naltrexone, and alcohol use in young adults.

Krysten W Bold, Lisa M Fucito, William R Corbin, Kelly S DeMartini, Robert F Leeman, Henry R Kranzler, Stephanie S O'Malley

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Experimental and clinical psychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Krysten W BoldDepartment of Psychiatry.
Lisa M FucitoDepartment of Psychiatry.
William R CorbinDepartment of Psychology, Arizona State University.
Kelly S DeMartiniDepartment of Psychiatry.
Robert F LeemanDepartment of Psychiatry.
Henry R KranzlerPerelman School of Medicine, University of Pennsylvania.
Stephanie S O'MalleyDepartment of Psychiatry.
Arizona State University · USUniversity of Pennsylvania · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Research Training Program in Substance Use PreventionT32DA019426 · NIDA · YALE UNIVERSITY · PI TAMI P SULLIVAN · 2005 to 2026
$7.5M
Naltrexone for Heavy Drinking in Young AdultsR01AA016621 · NIAAA · YALE UNIVERSITY · PI O'MALLEY, STEPHANIE S · 2007 to 2011
$3.0M
New Approaches to Smoking Cessation in Heavy DrinkersK23AA020000 · NIAAA · YALE UNIVERSITY · PI FUCITO, LISA M · 2011 to 2016
$755k
Difficulties with Self-Control and High-Risk Alcohol Use in Young AdultsK01AA019694 · NIAAA · YALE UNIVERSITY · PI LEEMAN, ROBERT F · 2010 to 2014
$705k
NCATS NIH HHS UL1 TR001863NIAAA NIH HHS K01 AA019694NIAAA NIH HHS K23 AA020000NIAAA NIH HHS R01 AA016621NIDA NIH HHS T32 DA019426
6 · The paper itself

Abstract

Heavy drinking among young adults is a serious public health problem. Naltrexone, an opioid antagonist, has been shown to reduce drinking in young adults compared to placebo and can be taken on a targeted (i.e., as needed) basis. Understanding risk factors for drinking and naltrexone effects within-person in young adults may help to optimize the use of targeted naltrexone. The current study was a secondary analysis of daily diary data from 127 (n = 40 female) young adults (age 18-25) enrolled in a double-blind clinical trial of daily (25 mg) plus targeted (25 mg) naltrexone versus placebo. Hierarchical linear models were used to examine the effects of daily affect, urge, and taking targeted medication on same-day risk of drinking to intoxication (defined as estimated blood-alcohol-concentration, BAC ≥ .08 g%). Results indicated urge significantly mediated within-person positive affect-drinking relations on a daily level. Specifically, positive affect was associated with greater urge to drink, which in turn was associated with greater odds of BAC ≥ .08 g%. Furthermore, days of greater positive affect and urge were associated with taking a targeted dose of medication, which reduced the likelihood of intoxication by nearly 23% in the naltrexone group compared to placebo. Gender and family history of alcohol dependence were examined as moderators of these daily level effects. These results provide further evidence of naltrexone's ability to reduce alcohol consumption in young adults and identify potential within-person risk processes related to heavy drinking that could inform alcohol-related interventions for this population. (PsycINFO Database Record

Indexed as

AffectAdolescentAdultAlcohol DrinkingCounselingCuesDouble-Blind MethodFemaleHumansMaleNaltrexoneYoung AdultNaltrexone

Identifiers

PMID27690505
PMCPMC5111359
OpenAlexW2529224864

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.